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TOM1L (target of Myb-1 Like) was identiﬁed as a binding partner for the full length and catalytically-active Lck in a yeast 2-
hybrid screening assay. Here we show that in Jurkat T cells stimulated by CD3/CD28 coligation where the expression of TOM1L is
reduced by lenti virus mediated-siRNA results in a dramatically lower IL-2 production. The production of IL-2 in siRNA treated
cells stimulated with PMA/ionomycin was not aﬀected indicating an involvement of TOM1L in a pathway proximal of TCR and
CD28. The coexpression of Fyn with TOM1L increased the level of the phosphorylated form of Fyn indicating that TOM1L has
the ability to activate Fyn. The ability of TOM1L to activate Fyn was further shown in a kinase assay using angiotensin II as a
substrate. By confocal microscopy, we show that the expression of TOM1L in non-treated HeLa and SK-N-SH cells colocalizes
with the mitochondrial membrane but not with lysosomal compartments or the trans-Golgi network. Furthermore, we show that
the over-expression of TOM1L in Jurkat cells causes an increase of the STAT3 expression . Based on our results, we here propose
that TOM1L is involved in a novel signaling pathway that is important for the IL-2 production in T cells.
Copyright © 2009 Ahmed Elmarghani et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
The function and property of the TOM1L (target of Myb-1
Like)genearetoalargeextentunknown.TOM1Lisaparalog
of TOM1 [1] and belongs to a new family of proteins con-
taining an N-terminally located VHS (Vps27p/Hrs/Stam)
domain and a central GAT (GGA (Golgi-localizing, γ-
adaptin ear domain homology, ADP-ribosylation factor
(Arf)-binding protein and Tom) domain. The GAT domain
of both TOM1L and Tom1 has the ability to bind ubiquitin
and Tollip (Toll-interacting protein), whereas the C-terminal
regionsoftheTom1-familyproteinsinteractwithclathrin[2,
3]. Tollip is a negative regulator of signaling downstream of
the IL-1 receptor and the Toll-like receptors [4, 5]. Inhibition
by Tollip is mediated through its ability to suppress the
activity of the IL-1 receptor associated kinase (IRAK).
When TOM1L-proteins are coexpressed with Tollip, they are
associated with the endosomes to where they recruit clathrin
[3]. The interaction of TOM1L-proteins with ubiquitin and
clathrin suggests a functional role in sorting proteins via
multivesicular bodies (MVBs) to lysosomes and subsequent
degradation. Alternatively, the proteins are recycled to the
trans-Golgi network (TGN) or the plasma membrane. Mass
spectrometry has been used to identify proteins which were
speciﬁcally tyrosine-phosphorylated, or complexed with a
tyrosine-phosphorylated protein, as a result of ﬁbroblast
growth factor receptor-1 (FGFR-1) overexpression in human
293T cells [6]. Among the identiﬁed proteins was Tom1L,
which has not previously been described in FGFR signaling
and was proposed to be a new docking molecule in FGFR-1
signaling [6].
The kinase activity of Src-family kinases is dramatically
increased by the direct binding of proteins to the SH3-
domain that destabilizes the intramolecular structure of Src-
family kinases [7, 8]. Thus, it is therefore of great importance
to identify proteins, which contain binding domains for2 Mediators of Inﬂammation
the SH3 domain and determine whether they can regulate
the kinase activity. Most SH2 and/or SH3 binders increase
Src-family activity in vivo and exhibit mitogenic and/or
transforming activity [9, 10].
Activation of the Src-family kinases Lck and Fyn is
central to the initiation of TCR signaling pathways [11].
One of the ﬁrst signaling events in activation of T-helper
cells (Th) by antigen presenting cells (APCs) is that Lck
becomes phosphorylated and thereby activated. How Lck
is activated during TCR engagement has not been fully
deﬁned. TCR-cross-linking alone does not stimulate Lck
autophosphorylation and CD45, which is an important
phosphatase regulating the activity of Src-family kinases
and signaling in lymphocytes [12], is not required for this
process [13]. The CD4 molecule recruits Lck to the T-
cell/APC interface, whereas CD28 is suggested to sustain Lck
activation [13].
The mouse homolog of TOM1L, Srcasm (Src activating
andsignalingmolecule),hasbeenshowntointeractwithFyn
in a yeast two-hybrid screen of a murine keratinocyte library
[14]. Srcasm serves as a substrate for Fyn and activates Fyn
kinase and is also capable of interacting with Grb2 and the
regulatory subunit of phosphoinositide 3-kinase, p85, in a
phosphorylation-dependent manner [14].
2.MaterialsandMethods
2.1. Cell Lines. A human leukemic T-cell line, Jurkat, that
expresses the large T antigen of SV40 virus was grown
in RPMI 1640 medium supplemented with 10% fetal
calf serum, 2mM glutamine, and penicillin/streptomycin.
Human kidney cells, 293T, HeLa SK-N-SH cells were grown
in DMEM supplemented with 10% bovine calf serum and
penicillin/streptomycin.
2.2. Tom1L Antibodies and Immunohistochemistry. The frag-
ment of the far C-terminal end of the TOM1L gene
encoding amino acids 243–476 was cloned in pGEX-KG
(Amersham Pharmacia Biotech). The TOM1L-GST fusion
proteins were expressed in BL21 or XL1-Blue Escherichia
coli. GST fusion proteins bound to glutathione Sepharose 4B
(Amersham Pharmacia Biotech) were eluted in 50mM Tris–
HCl pH 8.0 containing 5mM reduced glutathione (Sigma,
MO). All DNA constructs were veriﬁed by DNA sequence
analysis. To produce anti-TOM1L antibodies, rabbits were
immunized with an emulgate containing equal amounts of
pTOM1L-GST and mineral oil. At diﬀerent time points after
immunization, the rabbits were bled and serum was isolated.
Immune histochemistry performed using confocal ﬂuores-
cence microscopy. Cells were placed on to collagen type-I
coated cover slips and ﬁxed with 3.7% paraformaldehyde in
PBS containing 2% sucrose. The cells were incubated with
the anti-TOM1L antibodies for 2 hours at room temperature
washed with PBS. This was followed by incubation with the
Alexa Fluor488 (green-ﬂuorescent) or Alexa Fluor568 (red-
ﬂuorescent) conjugated secondary antibody (no. A11034,
no. A11036 Molecular Probes, Invitrogen, Carlsbad, CA)
for 1h at room temperature. MitoTrackerRed (no. M7512
Molecular Probes, Invitrogen, Carlsbad, CA) was used to
visualize the mitochondria according to the procedure
recommended by the manufacturer.
2.3. Transfection, Western Blotting and Immunoprecipitation.
To prepare full length TOM1L, DNA for transfection was
RNA isolated from Jurkat T cells (RNeasy easy kit, Qia-
gen) and used for subsequent cDNA synthesis (Amersham
biotech) followed by PCR. TOM1L was cloned into pCS3 +
MT to append six Myc-tagsto the amino terminus. Transient
transfection was performed as described earlier [15]. 293T
cells were seeded at 3 × 105 cells per 6cm gelatin-coated
Petri dishes the day prior to transfection. Forty-eight hours
after transfection with Lck (pCEP4), Fyn (pCS3) alone or
together with Myc-tagged TOM1L were cells resuspended in
1mLoflysisbuﬀer (1% Nonidet-P40, 20mM Tris pH 8.4,
150mM sodium chloride, 2mM EDTA, and 200μMs o d i u m
vanadate).Lysateswereclariﬁedbycentrifugationat34,000g
for 30 minutes at 4◦C. After preclearing with Protein-A
Pansorbincells(Calbiochem,CA),thelysateswereincubated
for 30–40 minutes at 4◦Cw i t h1μL of the speciﬁed primary
antiserum followed by a second 60-minute incubation with
Protein A Pansorbin cells. Immunoprecipitates were washed
two to three times in lysis buﬀer. Immunoprecipitates and
cell lysates were subjected to SDS–PAGE and transferred to
Immobilon-P (Millipore, MA) for Western blotting (Bio-
Rad, CA). Immobilon-P ﬁlters were blocked by incubation
in rinse buﬀer (10mM Tris pH 7.4, 150mM NaCl, and
0.1% NaN3), supplemented with 3% bovine serum albumin
and then stained with monoclonal anti-Myc antibody, rabbit
anti-Lck antibodies, or rabbit anti-phosphotyrosine anti-
bodies. Bound antibodies were detected with 125I–protein
A (Amersham Pharmacia Biotech, NJ) and the Typhoon
8600 Variable Mode Imager (Molecular Dynamics, CA). For
siRNA experiments, the cells were lysed in lysis buﬀer (1%
NP-40, 20mM Tris 7.6 pH, 150mM NaCl, 5mM EDTA at
2 × 107 cell/mL supplemented with phosphatase inhibitors)
(phosphatase proteases inhibitor (no. SC 24948, Santa Cruz,
CA)). The cell lysates were subjected to SDS–PAGE and
transferredtonitrocellulosemembrane(HighbondECL,no.
613-3555, Amersham) for Western blotting (Bio-Rad, CA).
The anti-TOM1L antibody was detected by goat-anti rabbit
IgG conjugated with alkaline phosphatase (S3731, Promega,
WI) and Western Blue Stabilized Substrate (S3841, Promega,
WI).
2.4. Yeast 2-Hybrid Assay. Competent AH109 yeast cells of
Saccharomyces cerevisiae (Clontech, Palo Alto, CA, USA)
containing four reporter genes (ADE2, HIS3, lacZ and
MEL1), under the control of three distinct GAL4-responsive
promoters were used in a yeast 2-hybrid assay. A human
thymus cDNA library (Human Thymus MATCHMAKER
cDNA Library, pACT-2 vector, Clontech) with about 3 × 106
independent clones containing the activation domain (AD)
of the GAL4 was used as prey. The bait was Lck cloned in the
pGBT9 plasmid (Clontech) containing the binding domain
(BD). Selected AD containing plasmids clones was ampliﬁed
andthenucleotidesequencesweredeterminedusingpACT-2
speciﬁc primers.Mediators of Inﬂammation 3
.......RATLGELNTMNNQLSGLNFSLPSSDVTNNLKPSLHPQMNLLALENTEIPPFAQRTS
328
QNLTSSHAYDNFLEHSNSVFLQPVSLQTIAAAPSNQSLPPLPSNHPAMTKSDLQPPNYYEVMEFDPLAPAV
TTEAIYEEIDAHQHKGAQNDGD
476
SH3-binding domain
P-Tyr motif
Figure 1: Amino acid sequence of the TOM1L clone that was picked up seven times in the yeast 2-hybrid assay. The SH3-binding domain
(LPPLP) and the phosphotyrosine motif (P-Tyr) at the C-terminus of TOM1L are marked.
2.5. Lentivirus and siRNA. Lentivirus was harvested by
centrifugation of the supernatant from 293T cells cotrans-
fected with the third generation of HIV-based vectors with
a conditional packaging system [16, 17]. Two 64-mere
oligonucleotides (5
  GATCCCCATCCAACTTACCTTGTC-
ACTTGAAGAGAGTGACAAGGTAAGTTGGATTTTTTG-
GAAA3
 ) forming a hairpin containing the DNA-sequence
for siRNA and restriction enzyme sequences were annealed
and cloned into pSUPER SK(+) having the H1-RNA
promoter. This sequence including the H1-RNA promoter
was then subcloned into the transfer vector cPPT-GFP
(p156RRLsinPPTCMVGFPPRE) using EcoR I/Kpn I. 293T
cells were transfected with 10μg of cPPT-GFP (containing
the siRNA construct or empty), 6.5μg of pRRE, 2.5μgo f
pRev, and 3.5μg of pVSV-G vectors (kind gift from Inder
Verma lab, Salk inst., La Jolla) using the Lipofectamine 2000
system (Invitrogen, CA).
2.6. ELISA. Supernatants of Jurkat cells (2.5 × 105 cells/well,
96-well TC plate) were harvested after 48 hours of stimu-
lation with plate bound anti-CD3 (MAB100) and soluble
anti-CD28 (MAB342) -antibodies (R and D Systems, Min-
neapolis, MN). Amount of IL-2 in the supernatants was
quantiﬁedaccordingtheELISA-kitprovidedbyeBiosciences,
La Jolla, CA. Alternatively were Jurkat cells stimulated with
50ng/mL of PMA plus 0.5μg/mL of ionomycin for 48 hours.
Data represents one out of three experiments performed
in triplicates. The Student T-test was used for statistical
analysis.
2.7. In Vitro Kinase Assay. Immunoprecipitates were incu-
bated with 5μCi of (γ-32P) ATP (Amersham Pharmacia
Biotech) and 2mM (Val5)-angiotensin II (Sigma) as an
exogenous substrate in 1,4-piperazinediethanesulfonic acid
(PIPES) kinase buﬀer (40mM PIPES pH 7.0, 10mM
MnCl2) for 1, 3, and 5 minutes at room temperature. The
reactions were stopped at the indicated times by adding
5% trichloroacetic acid and centrifuged at 10,000g for 10
minutes at 4◦C. Supernatants were subsequently absorbed
onto P81 phosphocellulose paper (Whatman, U.K.). The
phosphocellulose paper was washed with 0.5% phosphoric
acid to remove unincorporated (γ-32P) ATP. Incorporated
γ-32P was measured using liquid scintillation counting.
2.8. Luciferase Assay with the STAT3 Reporter. T-antigen
J u r k a tc e l l sw e r et r a n s f e c t e dw i t h0 . 6μg of ﬁreﬂy luciferase
reporter STAT3 (Signal-transducer-andactivator-of-tran-
scription-3) and 0.6μg of each experimental plasmid DNA.
Transfections were performed with the lipofectamine 2000
(Invitrogen). Included in each transfection was 25ng of a
reporter construct that expresses Renilla luciferase under
the control of the β-actin promoter. The luciferase assay
was performed using the Promega Dual-Luciferase Reporter
system (Promega, WI). 48 hours after the transfection,
approximately 2 × 106 cells were washed in cold PBS and
lysed in 100μLo fl y s i sb u ﬀer (Promega) for 10 minutes at
4◦C. Twenty μL from each lysate was mixed with 100μL
of assay buﬀer (Promega) immediately prior to reading in
a Berthold Lumat LB 9507 luminometer (Perkin–Elmer,
MD). The luciferase assay was quenched by adding 100μL
of Stop and Glo (Promega). The activity of Renilla luciferase
in each sample was then immediately measured and used to
normalize the luciferase data.
2.9. Statistical Analysis. The data are presented with means
and SEM. The Student T-test was used to analyze the data.
A P-value <. 05 was considered statistically signiﬁcant. (∗)
= P-value <. 05 and (∗∗) = P-value <. 01.
3. Results
3.1. TOM1L and Fyn Activity. We identiﬁed TOM1L as
a binding partner to Lck in a yeast 2-hybrid screening
assay using full length catalytically-active Lck as bait. Seven
clones from a human thymus cDNA library containing DNA
sequences of TOM1L were picked up as binding partners
to Lck (Figure 1). For this reason was TOM1L chosen for
further functional studies. The TOM1L clone contains an
SH-3 binding domain sequence at amino acids 421–425
(LPPLP) and a P-Tyr motif (YEEI) at amino acids 460–
463 (Figure 1). 293T cells were transfected transiently with
plasmids encoding TOM1L alone or TOM1L together with
Lck or Fyn in order to examine the role of TOM1L on
the activity of Lck and Fyn. In lysates from 293T cells
where TOM1L was coexpressed with Fyn (Figure 2(a))o r
Lck (Figure 2(b)), the amount of phosphorylated proteins
(anti-PTyr staining) increased considerably, indicating that4 Mediators of Inﬂammation
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Figure 2: (a) 293T cells transfected with plasmids encoding Fyn alone or together with Myc-tagged full length TOM1L. Fyn and TOM1L
proteins were isolated by immunoprecipitation using anti-Fyn, or anti-Myc antibodies and assayed by SDS−PAGE and immunoblotting
as described in material and methods. Immunoblots were analyzed with primary anti-phosphotyrosine (anti-PTyr), anti-Fyn or anti-Myc
–antibodies, respectively. (b) 293T cells transfected with plasmids encoding Lck alone or together with Myc-tagged full length TOM1L.
Lck and TOM1L proteins were isolated by immunoprecipitation using anti-Lck or anti-Myc antibodies and assayed by SDS−PAGE
and immunoblotting as described in material and methods. (c) Kinase assay: Anti-Fyn immunoprecipitates were incubated with 5μCi
of (γ-32P) ATP and 2mM (Val5)-angiotensin II as an exogenous substrate in PIPES kinase buﬀer for 1, 3, and 5 minutes at room
temperature.Mediators of Inﬂammation 5
(a) (b) (c)
Figure 3: Cellular expression of TOM1L in SK-N-SH neuroblastoma cells examined by confocal microscopy. Confocal imaging of cells
stainedwithantibodiesagainstTOM1L(red)(a),normalrabbitserum(b)orantibodiesagainstTOM1LtogetherwithrecombinantTOM1L
(c). Cells were stained with DAPI (blue) in all images to visualize the localization of the nucleus.
(a) (b)
(c) (d)
Figure 4: Confocal imaging of HeLa cells stained with antibodies against TOM1L (red) and anti-trans-Golgi network. Individual images
were separated digitally: (a) anti-TOM1L (red), (b) anti-trans-Golgi network (green), and merged images (c). (d) HeLa cells stained with
anti-TOM1L (red) and anti-Cathepsin D antibodies (green). Cells were stained with DAPI (blue) to visualize the localization of the nucleus.
the overexpression of TOM1L causes an overall increased
kinase activity in these cells. Coexpression of Fyn or Lck
with TOM1L increased the level of the phosphorylated
form (anti-PTyr staining) of anti-Fyn immunoprecipitated
Fyn (Figure 2(a)) and anti-Lck immunoprecipitated Lck
(Figure 2(b)). This indicates that TOM1L has the ability to
activate both Fyn and Lck, although the increase of anti-
PTyr staining of the anti-Fyn immunoprecipitate was much
stronger compared with the anti-Lck immunoprecipitate.
The level of staining using anti-Fyn antibodies in anti-
Fyn immunoprecipitates from cells transfected with TOM1L
alone represents the endogenous level of Fyn (Figure 2(a)).6 Mediators of Inﬂammation
(a) (b) (c)
(d) (e) (f)
Figure 5: Cellular expression of TOM1L colocalize with the mitochondria. Confocal imaging of SK-N-SH neuroblastoma cells ((a)–(c)) or
HeLa cells ((d)–(f)) stained with MitoTracker Red and antibodies against TOM1L. Individual images were separated digitally: ((a) and (d))
MitoTracker Red (red), ((b) and (e)) anti-TOM1L (green), and merged images ((c) and (f)). Cells were stained with DAPI (blue) to visualize
the localization of the nucleus.
Endogenous levels of Lck in anti-Lck immunoprecipitates
fromcellstransfectedwithTOM1Lalonewerenotdetectable
(Figure 2(b)).
TOM1L was considerably phosphorylated in anti-Myc
immunoprecipitated lysates, where TOM1L was cotrans-
fectedwithFyn(Figure 2(a))o rLc k(Figure 2(b)),indicating
that TOM1L is a substrate for both Fyn and Lck.
The ability of TOM1L to activate Fyn was further
examined in a kinase assay using the substrate angiotensin
II (Figure 2(c)). The ability of Fyn to phosphorylate
angiotensin II in a 1-, 3- or 5- minute reaction increased
considerably in anti-Fyn antibody precipitates of lysates
where Fyn was cotransfected with TOM1L compared with
anti-Fyn antibody precipitates of lysates where Fyn was
transfected with an empty vector (Figure 2(c)).
3.2.IntracellularLocalizationofTOM1L. Inordertoexamine
the intracellular localization of TOM1L, a rabbit anti-
TOM1Lantibodywasmadeandimmunehistochemistrywas
performed using confocal ﬂuorescence microscopy. The SK-
N-SH neuroblastoma and HeLa cell lines were used for the
immune staining.
The intracellular expression of TOM1L was examined
by staining SK-N-SH neuroblastoma cells with the rabbit
anti-TOM1L antibody (Figure 3(a)). To examine the speci-
ﬁcity of the anti-TOM1L antibody, the same cells were
stainedwithnormalrabbitserum(Figure 3(b))orantibodies
against TOM1L together with recombinant TOM1L protein
(Figure 3(c)). We concluded that the anti-TOM1L antibody
speciﬁcally stained on organelle around the nucleus.
To identify which organelle that was stained by the anti-
TOM1L antibody, we used the anti-TGN38 for the trans-
Golgi network (Figures 4(a)-4(b)) and the anti-Cathepsin D
antibodies for lysomal compartments (Figure 4(d)). None of
these colocalized with anti-TOM1L antibody staining, how-
ever, we found a good match when merging the MitoTracker
Red staining with the anti-TOM1L antibody staining, as
shown in Figure 5(c) (SK-N-SH cells) and Figure 5(f) (HeLa
cells).
3.2.1. Reduction of the TOM1L Expression by siRNA and IL-2
Production. Since Fyn and Lck are predominately expressed
in T-cells, we performed siRNA experiments using Jurkat
T-cells to further investigate the functional role of TOM1L.
The siRNA experiments were performed by lenti virus-
mediated infection of a hairpin construct. The expression
of TOM1L was eﬃciently suppressed in Jurkat cells infected
with the hairpin construct as compared with cells infectedMediators of Inﬂammation 7
Vector siRNA Vector siRNA
TOM1L
IP: anti-TOM1L Lysates
Figure 6: The protein expression of TOM1L in whole lysates and
immunoprecipitated lysates (anti-TOM1L antibodies) examined
by western blot analysis in Jurkat cells after siRNA treatment.
The siRNA experiments were performed by lenti virus-mediated
infection of a hairpin construct. The expression of TOM1L was
eﬃciently reduced in cells infected with the hairpin construct
(siRNA) as compared with cells infected with a vector lacking the
hairpin construct (Vector).
with a vector lacking the hairpin construct (negative control)
(Figure 6). To examine the role of TOM1L in eﬀector T-
cell activation, the Jurkat cells were stimulated for IL-2
production by plate bound anti-CD3 antibodies and soluble
anti-CD28 antibodies. We found that the level of IL-2
production was signiﬁcantly lower in siRNA-infected cells
compared with negative control (Figures 7(a)and7(b)).This
eﬀect could not be seen in the same siRNA-infected cells
after stimulation with PMA plus ionomycin (Figure 7(c)),
indicating that the function of TOM1L is downstream and
proximal of TCR and CD28.
3.3. Over-Expression of TOM1L and STAT3. Jurkat cells
were transfected with plasmids encoding the STAT3 (Signal-
transducer-andactivator-of-transcription-3) ﬁreﬂy luciferase
reporter and TOM1L. The over-expression of TOM1L in T
cells caused a signiﬁcantly increased output from the STAT3
gene reporter (Figure 8).
4. Discussion
The function of TOM1L in T cells has not been described
earlier; however, the function as a negative regulator of
mitogenesis in epithelial cells stimulated with growth factors
has been proposed [18, 19]. It has been proposed that
Tom1L1negativelyregulatesSrcmitogenicsignalinginduced
by platelet-derived growth factor (PDGF) through modula-
tion of Src-receptor association [18]. Further has it proposed
that upon association with CHC (clathrin heavy chain)
will Tom1L1 reduce the level of Src in caveolae, thereby
preventing its association with the PDGF receptor, which is
required for the induction of mitogenesis [19]. Our results
suggest a mitogenic role of TOM1L in T cells, indicated by
the dramatically reduced IL-2 production in cells where the
expression of TOM1L was reduced by siRNA. A mitogenic
function of TOM1L in T cells was further indicated by the
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Figure 7: Il-2 production of stimulated Jurkat cells where the
expression of TOM1L was reduced by siRNA. The IL-2 production
was signiﬁcantly lower in stimulated cells infected with the hairpin
construct (siRNA) as compared with cells infected with a vector
lacking the hairpin construct (Vector). (a) Stimulation with plate
bound anti-CD3 (1μg/well) plus 1μg/mL of anti-CD28 antibodies,
48 hours, (b) stimulation with plate bound anti-CD3 (1μg/well)
plus 0.25μg/mL of anti-CD28 antibodies, 48 hours, (c) cells
stimulated with 50ng/mL of PMA plus 0.5μg/mL of ionomycin for
48 hours.8 Mediators of Inﬂammation
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Figure 8: Jurkat cells were transfected with a ﬁreﬂy luciferase
reporter for STAT3 (Signal-transducer-andactivator-of-transcrip-
tion-3) together with plasmids encoding TOM1L or the empty
plasmid construct. Included in each transfection was a reporter
construct that expresses Renilla luciferase under the control of
the β-actin promoter. 48 hours after the transfection, the cells
were washed and lysed followed by reading in a luminometer. The
activity of Renilla luciferase in each sample was used to normalize
the luciferase data.
increased expression level of STAT3 after overexpression of
TOM1L. STAT3 is known to be a substrate for SFK members
[20], and SFK inhibition in various carcinoma tumor cell
lines results in loss of STAT3 activity [21]. STAT3 is closely
linked with tumorigenesis and its role in cancer is indicated
by numerous avenues of evidence, including that STAT3 reg-
ulatestheexpressionofgenesthatmediateproliferation(e.g.,
c-myc and cyclin D1), suppress apoptosis (e.g., Bcl-xL and
survivin),orpromoteangiogenesis(e.g.,VEGF)(reviewedin
[22]). In a comprehensive genomic and expression proﬁling
study, of chromosome 17 in breast cancer cells, TOM1L
was recently identiﬁed as a novel candidate gene [23]. The
contrasting results about the mitogenic eﬀect of TOM1L
imply that the function of TOM1L is dependent on the cell
type and the way the cells are stimulated.
Reorganization of proteins around the T-cell/APC inter-
face, termed immunological synapse (IS) formation, plays
an important role in the initial steps and sustained acti-
vation of T-cells [13]. Very little is known about organelle
redistribution during IS formation in Th cells, however
and very interestingly, it recently has been shown that Th-
cell activation requires mitochondrial translocation to the
immunological synapse [24]. In this study, the authors show
that the redistribution of the mitochondria to the IS was
necessary to maintain Ca2+ inﬂux across the plasma mem-
brane and Ca2+-dependent T-cell activation. In the present
study, our immune histochemistry data suggest that the
TOM1L protein is localized to the mitochondrial membrane
in resting and nontransfected cells. The translocation of
the mitochondria to the IS during T cell activation could
hypothetically serve as explanation for how TOM1L could
interact with Fyn/Lck in vivo. This mechanism would be
possible for TOM1L since Lck/Fyn are bound to the plasma
membrane and proximal to the TCR and CD28 [11, 25].
5. Conclusions
Taken together, our results imply that TOM1L has a mito-
genic eﬀect in Jurkat T-cells and is involved in a novel cell
signaling pathway that is crucial for the IL-2 production
and STAT3 expression. Understanding the mechanisms that
control the activity of the Lck/Fyn in T cells is of great
importance for understanding the progression of cancer and
autoimmune disease.
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